Following on from information provided to NICE by the company in April 2019, the appraisal of Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1231 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019, the appraisal of Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 April 2019 | Suspended. The company have announced that durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy did not meet the primary endpoints of overall survival compared to standard-of-care chemotherapy in the Phase III EAGLE trial. Therefore NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual